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ABSTRACT
The cyclic growth, differentiation, and cell death of endo-
metrium represents the most dynamic example of steroid-driven
tissue turnover in human adults. Key effectors in these process-
es—matrix metalloproteinases (MMPs) and their specific inhib-
itors (TIMPs)—are regulated by ovarian steroids and, locally, by
cytokines. We used reverse transcription-polymerase chain re-
action to evaluate the expression of both transcriptionally reg-
ulated molecules such as estrogen receptor-a, progesterone re-
ceptor, and prolactin and a large array of MMPs and TIMPs
(MMP-1, -2, -3, -7, -8, -9, -11, -12, -19, -26, MT1-MMP, MT2-
MMP, MT3-MMP, TIMP-1, -2, -3). Altogether, three distinct pat-
terns of MMP and two patterns of TIMP expression were de-
tected in cycling endometrium: 1) MMPs restricted to the men-
strual period (MMPs-1, -3, -8, -9, -12); 2) MMPs and TIMPs ex-
pressed throughout the cycle (MMP-2, MT1-MMP, MT2-MMP,
MMP-19, TIMP-1, and TIMP-2); 3) MMPs predominantly ex-
pressed during the proliferative phase (MMP-7, MMP-11, MMP-
26, and MT3-MMP); and 4) TIMP-3, which, contrary to the other
TIMPs, shows significant modulations, with maximum expres-
sion during the late secretory and menstrual phases. These spe-
cific patterns of MMP expression associated with each phase of
the cycle may point to specific roles in the processes of men-
struation, housekeeping activities, angiogenesis, tissue growth,
and extracellular matrix remodeling.
female reproductive tract; gene regulation; menstrual cycle
INTRODUCTION
The endometrium is a unique dynamic tissue undergoing
extensive cyclic changes in response to fluctuations in ste-
roid hormone concentrations. In the course of the normal
menstrual cycle, it displays a regular sequence of growth,
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differentiation, and programmed breakdown [1]. The hu-
man genome sequence has revealed more than 500 genes
that encode proteases or protease-like proteins [2]. Among
these the matrix-metalloproteinases (MMPs), a group of 24
enzymes that degrade the extracellular matrix (ECM) and
basement membrane and process bioactive mediators, have
been the focus of much anticancer research and clinical
trials.
In the endometrium, MMPs are involved in matrix re-
modeling associated with perimenstrual phases [3, 4]. They
are synthesized as inactive zymogens, are either secreted or
expressed as transmembrane proteins, are inhibited by tis-
sue inhibitors of MMPs (TIMPs), and can hydrolyze ECM
and non-ECM proteins (such as adhesion molecules,
growth factors, and cytokines). They can be divided into
several distinct subgroups based on substrate specificity or
structural similarities: collagenases (MMP-1, -8, -13); ge-
latinases (MMP-2, -9); stromelysins (MMP-3, -7, -10, -11);
and membrane-type MMPs (MT-MMP1 to 6). An addition-
al miscellaneous group of MMPs includes MMP-12, MMP-
18, and MMP-19 to -26 [5, 6].
Beyond their clinical connective tissue-degrading func-
tions, MMPs regulate the activities of bioactive molecules
by proteolytic processing [7, 8]. For example, MMPs me-
diate cell surface-receptor cleavage and release, cytokine
and chemokine activation and inactivation, and the release
of apoptotic ligands. They also inactivate growth factor-
binding proteins and release mitogenic molecules from ma-
trix proteins. These cellular processes are all involved in
promoting aspects of endometrial cell proliferation, adhe-
sion, mesenchymal to epithelial transition during deciduas
formation, differentiation, angiogenesis, apoptosis, men-
strual breakdown, and host defense. MMP inhibitors are
therefore potentially useful for blocking endometrial re-
modeling and bleeding [9, 10].
In most adult tissues, the expression of MMPs is very
low [11], but it can be rapidly and drastically induced dur-
ing active tissue remodeling. Their proteolytic activities are
regulated by gene transcription, zymogen activation, and
specific inhibition by physiologic tissue inhibitors (TIMPs)
[12–16]. The expression profile of ‘‘classical’’ MMPs
(MMP-1, -2, -3, -7, -9, -11, and membrane-type [MT]1-
MMP), which were the first described and the most exten-
sively studied to date, and TIMPs has been determined in
endometrium by in situ hybridization and Northern blot,
and the proteins have been localized using immunohisto-
chemistry [17–21]. They are expressed at specific phases
during the menstrual cycle. Most MMPs show a maximal
expression during the perimenstrual phase and are unde-
tectable during the proliferative and secretory phases, but
few of them are expressed throughout the cycle [22].
Recently new members of the MMP family have been
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described, such as MMP-19, MMP-26 (endometase or ma-
trilysin-2), and MT-MMPs (1 to 6) [23–28]. MMP-26 has
marked structural similarities with MMP-7 but distinct sub-
strate specificity [29]. These MMPs are expressed in epi-
thelia and epithelial tumor cells [26, 27, 30]. It has therefore
been suggested that MMP-26 could play an important role
in ECM remodeling associated with rapid epithelial growth
and angiogenesis [27, 31].
MMP-19 expression in normal tissue is ubiquitous [23,
32] and could be involved in acute inflammatory angiogen-
esis [33]. Moreover, MMP-19 shows an unusual downreg-
ulation in invasive cancer.
MT-MMPs comprise a family of six transmembrane
MMPs. They are able to degrade various ECM components,
including native collagens [9]. The expanding recognized
roles of MMPs in complex regulatory and remodeling pro-
cesses has stimulated expression studies in various normal
tissues and pathological states (for a review see [7, 34]).
Because MMPs and TIMPs form a complex network of
interacting enzymes, sensitive and accurate determination of
their expression profile is required to evaluate their regula-
tion and specific roles. In this study, we used quantitative
reverse transcription-polymerase chain reaction (RT-PCR) to
precisely delineate the temporal expression patterns of six
recently described MMPs and compare them with that of the
interstitial collagenase (MMP-1), stromelysin 1 (MMP-3),
and gelatinase B (MMP-9), which culminate during men-
struation or with that of housekeeping gene permanently ex-
pressed such as gelatinase A (MMP-2).
MATERIALS AND METHODS
Tissues
Endometrial tissues were collected from healthy women with sponta-
neous, regular menstrual cycles (26–33 days) on a voluntary basis. Patients
with endometriosis, infertility, or irregular menstrual cycles and those on
hormonal treatment or oral contraception were excluded. Endometrial bi-
opsy samples were obtained with a Pipelle curette or by curettage. Patients
gave their informed consent, and the protocol was approved by the Uni-
versity Ethics Committee. Each sample was divided in two. One fragment
was fixed in buffered formalin for histological dating (Noyes criteria) by
a pathologist (V.F.) experienced in endometrial studies. The second was
immediately snap frozen and stored in liquid nitrogen. Samples were ex-
cluded when the histological dating was inconsistent with the date of the
patient’s last menstrual period. Thirty-three patients aged 20–45 yr (mean
33 yr) were included. The samples were classified according to classical
histologic criteria as early proliferative phase (EP, n 5 6); late proliferative
phase (LP, n 5 6); early (ES, n 5 6), mid- (MS, n 5 5), and late (LS, n
5 5) secretory phase; and menstrual phase (ME, n 5 5). We also validated
the histological tissue dating by comparison with the known profiles of
gene products that are hormonally regulated during the cycle. Indeed,
mRNA encoding the estrogen-a and progesterone receptors is downregu-
lated [35], but prolactin mRNA is upregulated during the late secretory
phase [36]. In our samples, the expression pattern of prolactin (PRL),
progesterone receptor, and estrogen receptor-a, measured by RT-PCR was
identical to that reported for the corresponding proteins, throughout the
cycle [35, 37–39] (data not shown).
RNA Extraction
Endometrial tissue biopsies were immediately snap frozen and stored
in liquid nitrogen until analysis. The frozen tissues were pulverized using
a Dismembrator (B. Braun Biotech International, GmBH, Melsungen, Ger-
many) and suspended in lysis buffer (5 M guanidine thiocyanate, 25 mM
sodium citrate, 17 mM N-lauroylsarcosine and 0.1 M 2-mercaptoethanol
[pH 7]). Total RNA was purified by cesium chloride ultracentrifugation
according to the procedure of Chirgwin et al. [40].
RT-PCR Amplification
RT-PCR amplification was performed using the GeneAmp Thermosta-
ble rTth reverse transcriptase RNA PCR kit (Perkin-Elmer, Branchburg,
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FIG. 1. Synthetic DNA standard used as
a template for mssRNA. A) Sequence of
the synthetic DNA standard. B) Succession
of the selected forward and reverse primer
pairs that allow reverse transcription-poly-
merase chain reaction amplification of
mRNA coding for TIMP-1, -2, -3, MMP-15,
-16 (open boxes). The black box corre-
sponds to the SP6 polymerase initiation
site in the pSPT18 plasmid.
NJ), specific pairs of primers (5 pmol each; Gibco BRL-Life Technologies,
Carlsbad, CA) (Table 1), 10 ng of total RNA and, when available, a known
copy number of an internal standard (mssRNA, see below) per 25 ml of
reaction mixture (final volume). Reverse transcription was performed at
708C for 15 min, followed by 2 min at 958C to denature RNA-DNA
heteroduplexes. For most transcripts, PCR amplification was run as fol-
lows: 15 sec at 948C, 20 sec at 688C, and 10 sec at 728C (number of cycles
as indicated in Table 1), followed by a final 2-min extension step at 728C.
For MMP-3 and -11, the cycling conditions consisted of 15 sec at 948C,
30 sec at 638C, and 30 sec at 728C (for 30 cycles). RT-PCR products were
resolved on 10% polyacrylamide gels and analyzed using a Fluor-S
MultiImager (BioRad, Hercules, CA) after staining with Gelstar dye (FMC
BioProducts, Rockland, ME).
Selection of Primers for RT-PCR
Pairs of primers (Table 1) for RT-PCR amplification were designed
according to the following criteria: (1) a theoretical melting temperature
of 728C (48C for G or C and 28C for A or T); (2) minimum complemen-
tarity between the forward and reverse primer sequences; (3) primers were
reverse and forward located on different exons to permit electrophoretic
discrimination between genuine RT-PCR products and products amplified
from contaminating DNA; (4) the length of the RT-PCR product ranged
between 155 and 270 bp, a size both permitting easy discrimination be-
tween specific and artifactual amplification products and producing good
yields. We also conducted BLASTn (National Center for Biotechnology
Information, Bethesda, MD) searches against dbEST and the nonredundant
set of GenBank, EMBL, and DDBJ database sequences to confirm the
total gene specificity of the nucleotide sequences chosen for the primers.
The specificity of the amplified PCR products was finally confirmed either
by restriction digest or sequencing.
The efficiency of the selected primer pairs for each human mRNA was
tested by RT-PCR using 10 ng of total RNA extracted from human pla-
centa or human dermal fibroblasts. All the RT-PCR products had the ex-
pected size. The assay was also performed using 50 ng of human DNA.
When detected, the reaction products were larger than the amplification
products obtained from cellular RNA, owing to the presence of intronic
sequences (not illustrated). No signal was detected in control samples free
of nucleic acid.
Construction and Use of Multistandard Synthetic RNAs
Synthetic RNAs were created to monitor, in each sample, possible var-
iations in the efficiency of RT-PCR amplification. These synthetic RNAs
have two main characteristics. First, they can be amplified by primers used
for RT-PCR amplification of the endogenous mRNA of interest. Second,
the size of their amplification product is different from the size of the RT-
PCR product amplified from the mRNA, permitting their discrimination
after electrophoresis. Generation of the synthetic standard RNA for MMP-
1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-11, MMP-14 mRNA, and
28S rRNA was done as previously described [41, 42]. MMP-12, MMP-
15, MMP-16, TIMP-1, TIMP-2, and TIMP-3 mRNA were monitored with
a second multistandard synthetic RNA (mssRNA). For the construction of
this multistandard RNA, double-stranded synthetic DNA (Fig. 1a) was
synthesized as follows: the first half (bases 1 to 264) and the second half
(bases 271 to 510) were generated separately by annealing and ligating
eleven (first half) and nine (second half) partially overlapping phosphor-
ylated oligonucleotides. The relevant oligonucleotides (1 pmol each) were
mixed and incubated at 808C for 5 min before slow cooling to room tem-
perature to permit sequential annealing. Ligation (T4 DNA ligase; Invitro-
gen Life Technologies, Merelbeke, Belgium) was performed at 248C for
3 h. The ligation mixture was submitted to 25 cycles of PCR (948C for
20 sec, 668C for 20 sec, 728C for 45 sec).
For the first half of the final construction, the following oligonucleotides
flanked by Pst I and Bam HI restriction sites (underlined) were used for
PCR amplification: 59-AAAACTGCAGGGCATCCTCTTGTTGCTATC-
ACTG-39 and 59-TATAGGATCCGTCATCAGCAGAGAGGCGAAATGT-
39. For the second half, the oligonucleotides 59-TTAAGGATCCCCAGC-
GTTATGAGATCAAGATGAC-39 and 59-AAAAGAATTCAGGAAGCTT-
CCACCAGAAGAACCA-39 were used, amplifying a PCR product flanked
by Bam HI and Eco RI restriction sites (underlined). After cleavage with
Pst I and Bam HI (first half) or Bam HI and Eco RI (second half), the PCR
products were purified on agarose gel and sequentially cloned into pSPT18
transcription vector (Roche Diagnostics Belgium, Vilvoorde, Belgium)
(Fig.1b). A sequence-verified construct was then linearized, purified, and
used as template for RNA synthesis (SP6 polymerase, SP6/T7 transcrip-
tion kit; Roche Diagnostics Belgium). The resulting mssRNA was then
purified and quantified. RT-PCR amplification of this mssRNA with the
different pairs of primers generated amplification products larger (245 to
271 bp) than those obtained from the cellular RNA (155 to 210 bp, see
Table 1), enabling them to be discriminated by electrophoresis.
As previously described [41], some preliminary assays were performed
to define the number of copies of the mssRNA to be added to each sample
to monitor variations in efficiency of the RT. The noncompetitive condi-
tions, as defined by Freeman et al. [43], allowed quantification of the
various RNAs. We validated our RT-PCR quantification assay by perform-
ing RT-PCR reactions with a defined and constant number of copies of
mssRNA and increasing amounts of cellular RNA (0.5 to 10 ng). The ratio
between the signals for a specific mRNA and the mssRNA was shown to
increase linearly with the amount of cellular RNA. In all assays, the actual
concentration of the specific mRNA (calculated as the mssRNA copy num-
ber equivalent) was expressed per unit of 28S rRNA measured in the same
RNA solution.
No mssRNA was available for RT-PCR quantification of MMP-7,
MMP-19, MMP-26, PRL, progesterone receptor, and estrogen receptor a
mRNA. Their level of expression was thus normalized to 28S mRNA
quantified in the same sample.
Statistical Analysis
For each RNA sample, RT-PCR quantification was performed three
times. Data expressed in the figures represent the means 6 SEM for each
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FIG. 2. Analysis of RT-PCR of MMPs that
are upregulated during the menstrual
phase (MMP-1, -3, -8, -9, -12) in endome-
trial tissue from regularly cycling women
throughout the menstrual cycle. A) Repre-
sentative gels of samples from the early
proliferative (EP: lanes 1 and 2), late pro-
liferative (LP: 3 and 4), early secretory (ES:
5 and 6), late secretory (LS: 7 and 8), and
menstrual phases (ME: lanes 9 to 13). En-
dogenous target mRNAs and mssRNA are
coamplified with the same primers, but
their products differ in size. Arrows indi-
cate RT-PCR products from the mssRNA
and the endogenous mRNA. B) Densito-
metric quantification of the mRNA levels
normalized with 28S rRNA. Results are
means 6 SEM. The actual concentration of
the specific mRNA (calculated as the
mssRNA copy number equivalent) was ex-
pressed per unit of 28S rRNA measured in
the same RNA solution. The menstrual
phase was compared with the values of all
other phase (EP, LP, ES, MS, and LS) and
found to be significantly different (***P ,
0.0001).
group (n $ 5). Results for the different groups were compared using the
Kruskal-Wallis test, and any significant differences were further analyzed
by pairwise comparison using the Mann-Whitney test. P values , 5%
were considered statistically significant.
RESULTS
MMP Expression
We used RT-PCR to examine the expression of a large
array of MMPs and TIMPs in the cycling endometrium. In
addition to its high sensitivity, RT-PCR permits the detec-
tion of minute amounts of specific mRNA. Moreover, by
using an internal RNA standard to monitor the entire RT-
PCR amplification process, the method becomes semiquan-
titative [42, 44].
We examined the expression, at the mRNA level, of a
large array of MMPs and TIMPs (listed in Table 1) during
the endometrial cycle. An example of the expression profile
of MMPs and TIMPs analyzed is shown in Figure 2A to
5A for representative samples of each phase of the cycle.
Three patterns of expression were observed. First, A
‘‘menstrual’’ pattern included MMPs almost exclusively ex-
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FIG. 3. Analysis of RT-PCR of late prolif-
erative MMPs that are upregulated during
the proliferative phase (MMP-7, -11, -MT3,
-26). A) Representative gels as described
in Figure 2A. B) Densitometric quantifica-
tion of the RT-PCR products as described
in Figure 2B. The early proliferative (EP)
phase was compared with the early secre-
tory (ES), midsecretory (MS), and late se-
cretory (LS) phases for MMP-7 and -11
(**P , 0.001) and with late proliferative
(LP), ES, MS, and LS phases for MT3-MMP
(*P , 0.05) and MMP-26 (**P , 0.001).
pressed during menstruation. This included mRNAs for
MMP-1, MMP-3, MMP-8, MMP-9, and MMP-12, which
were not or minimally detected during the proliferative and
secretory phases. These MMPs showed markedly increased
expression during the menstrual phase (more than 10-fold
for MMP-9, P , 0.0001) (Fig. 2). Second, a ‘‘proliferative’’
pattern involved MMPs largely expressed during the pro-
liferative phase. Transcripts of MMP-7, MMP-11, MT3-
MMP, and MMP-26 were detected permanently but with
significant variations throughout the cycle (Fig. 3). The lev-
els of MT3-MMP and MMP-26 mRNAs were maximal
during the proliferative phase and subsequently declined to
reach basal values during the late secretory phase and men-
struation. On the contrary, MMP-7 and MMP-11 exhibited
a repression at midcycle (more than 10-fold for MMP-7, P
, 0.0001 and 2- to 3-fold for MMP-11, P , 0.001). Third,
a ‘‘housekeeping gene’’ (permanent) profile concerned
MMP mRNAs expressed throughout the cycle, with less
than 2-fold variation. A moderate increase in the mRNA
levels of MMP-2, MT1-MMP, and MMP-19 was observed
during the menstrual phase (Fig. 4). Only the 2-fold in
MT1-MMP mRNA levels during the menstrual phase was
found to be statistically significant (Fig. 4).
TIMP Expression
TIMP-1, -2, and -3 mRNAs were detected throughout
the cycle (Fig. 5) but with distinct profiles: TIMP-1 mRNA
levels increased during the secretory and menstrual phases
in comparison with the proliferative phase, but these chang-
es were not statistically significant. TIMP-2 levels were sta-
ble. By contrast, TIMP-3 mRNA levels increased signifi-
cantly (2- to 3-fold) during the late secretory and menstrual
phases when compared with the proliferative and early se-
cretory phases (P , 0.001).
DISCUSSION
The cyclic proliferation, neoangiogenesis, secretory dif-
ferentiation, predecidua formation, inflammatory cell infil-
tration, extensive apoptosis, and tissue breakdown of the
endometrial functional layer are associated with a coordi-
nated selective up- and downexpression of at least 13
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FIG. 4. Analysis of RT-PCR of MMPs that
are expressed throughout the cycle, with
minor variation (MMP-2, MT1-, MT2-
MMP, and MMP-19). A) Representative
gels as described in Figure 2A. B) Densito-
metric quantification of the RT-PCR prod-
ucts as described in Figure 2B. Results are
means 6 SEM. For MT1-MMP, a signifi-
cant increase of mRNA level was observed
in the menstrual phase, compared with the
late proliferative (LP) and all secretory
phases of the endometrial cycle (P ,
0.005).
MMPs and their physiological inhibitors, TIMPs. Three
patterns of MMPs and two of TIMPs expression were dis-
tinguished.
The first pattern is that of ‘‘classical’’ MMPs expressed
only during the menstrual phase (MMP-1, MMP-3, MMP-
8, MMP-9, and MMP-12). Our data concerning MMP-1,
-3, and -9 confirm previous studies performed by Northern
blot, in situ hybridization, or immunolocalization [3, 18,
19, 45]. This pattern of expression in normal endometrium
highlights the pivotal role of MMPs in matrix degradation
associated with menstruation [46]. Provided that corre-
sponding changes in protein levels follow a similar pattern,
a proteolytic imbalance promoting tissue breakdown would
occur during menstruation because TIMP-1 and -2 expres-
sion remained essentially unchanged.
To our knowledge, this is the first report of the expres-
sion of MMP-8 and MMP-12 in the endometrium. The pre-
cise cellular origin of these MMPs remains to be elucidated
by appropriate in situ hybridization and immunohistochem-
ical studies. However, their expression during the menstrual
phase coincides with infiltration of the functionalis layer by
transient immune cells, and particularly by neutrophils, eo-
sinophils, and macrophages, that are known to produce
these enzymes [47]. In vitro studies have previously shown
that MMPs-1, -3, and -9 are abundantly secreted by endo-
metrial stromal cells on progesterone withdrawal [3, 48].
These cells might also secrete MMP-8 and -12 because in-
flammatory cytokines present in menstrual endometrium
are known to induce their expression by stromal cells dur-
ing the acute phase of inflammatory reactions in other set-
tings [49].
The second pattern was that of MMPs expressed
throughout the cycle (MMP-2, MMP-19, MT1-MMP, and
MT2-MMP). Except for MT1-MMP, the mRNA levels of
these factors remained unchanged throughout the cycle. A
moderate increase was consistently observed during men-
struation but was only statistically significant for MT1-
MMP. In contrast to the menstrual MMPs (pattern 1), these
MMP mRNAs were not downregulated during the secretory
phase. These enzymes may thus exert housekeeping activ-
ities. Previous immunolocalization and in situ hybridization
studies [18, 21] have shown that MT1-MMP and MMP-2
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FIG. 5. Analysis of RT-PCR of TIMPs-1, -2, and -3. A) Representative gels
as described in Figure 2A. B) Densitometric quantification of the RT-PCR
products as described in Figure 2B. Results are means 6 SEM. For tissue
inhibitors of MMP-3, a significant increase of the mRNA level was de-
tected in the late secretory (LS) and menstrual phase (ME), compared with
the proliferative and early secretory (ES) or midsecretory (MS) phase (P ,
0.001).
are predominantly produced by stromal fibroblasts in other
tissues. Because MT1 and MT2-MMPs are physiological
activators of pro-MMP-2, their coordinate expression sug-
gests that these proteases could collectively be produced in
active form and contribute to the matrix remodeling
throughout cycle. Despite their marked molecular and
structural homologies, the MT1 to MT3 MMPs are differ-
entially regulated. Our study confirms previous immuno-
histochemical observations that MT1-MMP is predomi-
nantly expressed during menses in coordination with most
other MMPs, but MT2-MMP is expressed throughout the
cycle [21]. MMP-19 has previously been localized in other
tissues in vascular endothelial and smooth muscle cells [33]
and has therefore been assumed to play a role in angiogen-
esis [32]. Blood vessel growth and remodeling in the en-
dometrium are detectable throughout the cycle. MMP-19
expression throughout the menstrual cycle is thus compat-
ible with its documented angiogenic role [50, 51].
The ‘‘proliferative’’ MMPs (MMPs-7, -11, -26, MT3-
MMP) represent the third expression pattern. Our data con-
firm previous observations that MMP-7 and -11 expression
is drastically downregulated by progesterone and strongly
upregulated during menses [52, 53]. In addition we show
here that MT3-MMP and MMP-26 are poorly expressed
during the mid- and late secretory phases. Their expression
is not reactivated on progesterone withdrawal during men-
ses, indicating that these enzymes are probably not asso-
ciated with cellular apoptosis and tissue breakdown during
menstruation [54].
MMP-26 is structurally related to MMP-7. Their ex-
pression is restricted to epithelial tumor cells and epithelial
cells of the endometrium [27, 29, 31, 55]. We show here
that it is enhanced during the proliferative phase of the
cycle (Fig. 3). It remains to be determined whether MMP-
26 plays specific roles in the cell proliferation, rapid glan-
dular growth, stromal expansion, and angiogenesis ob-
served in the preovulatory follicular phase. The require-
ment of growth factors and cytokines release from the en-
dometrial ECM by MMPs supports this hypothesis [5].
The pattern of MT3-MMP mRNA expression—minimal
during menses and maximal during the early proliferative
phase—is compatible with its documented morphogenetic
and angiogenic role in the embryo [56, 57].
Finally, among the TIMPs, only TIMP-3 showed signif-
icant cyclical variations. TIMP-1 and TIMP-2 were ex-
pressed at comparable levels throughout cycle. Maximal
TIMP-3 expression occurred in the late secretory phase,
when endometrial stromal cells underwent predecidual dif-
ferentiation. Although TIMP-3 has been considered a mo-
lecular marker for decidualization that would limit tropho-
blast invasion [58, 59], others have shown in addition that
TIMP-3 is also produced in endometrium by nondecidual-
ized stromal and endothelial cells [10, 20].
MMPs are tightly regulated at the transcriptional and
posttranscriptional levels and are also controlled at the pro-
tein level by their activators and inhibitors. This study fo-
cused only on MMP transcript levels, which do not nec-
essarily correspond to protein levels, and the latent proen-
zyme zymogen is not necessarily secreted and activated.
Furthermore, regulation of activated MMP enzymes by
TIMPs adds to the complexity of the situation. A great deal
of work remains to understand the roles of MMPs in en-
dometrial physiology, but this study provides the ground-
work for future experiments designed to determine which
of the MMPs are locally transcribed during the different
phases of the cycle.
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MMPs have functions other than matrix remodeling and
endometrial breakdown. Their substrates, in addition to
components of the EM encompass cytokines-chemokines
and their ligands (either in soluble forms or bound to the
cell surface) as well as cell-adhesion molecules of the cad-
herins and integrins family, their own zymogen forms, and
other MMPs and proteinase inhibitors such as serpins (re-
viewed in [34]). Our study gives a comprehensive view of
the pattern of endometrial MMPs throughout the menstrual
cycle. It further supports the concept that MMPs expression
is associated with multiple biological activities by several
cell types. In addition to their precise identification by im-
munohistochemical and in situ hybridization, the recently
developed methodology of protease degradomics—the ap-
plication of genomic and proteomic approaches to identify
the protease and protease-substrate repertoires or ‘‘degra-
domes’’—on the endometrium would be most useful to bet-
ter delineate the multiple roles of MMPs in endometrial
physiology in vivo [2]. This knowledge will ultimately fa-
cilitate the identification of new pharmaceutical targets to
treat MMP-related disease such as endometriosis, adeno-
myosis, shedding, or unwanted bleedings.
In conclusion, this study highlights the complex regu-
lation of the MMP family in the endometrium. It points to
specific roles of MMPs that are differentially expressed dur-
ing the various phases of the cycle. MMPs expressed during
the proliferative phase may exert functions associated with
rapid tissue growth and angiogenesis, and ‘‘menstrual
MMPs’’ degrade ECM components, leading to tissue break-
down on progesterone withdrawal.
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